GVR Report cover COVID-19 Sample Collection Kits Market Size, Share & Trends Report

COVID-19 Sample Collection Kits Market Size, Share & Trends Analysis Report By Product (Nasal Swabs, Viral Transport Media), By Application, By Site of Collection, And Segment Forecasts, 2021 - 2027

  • Published Date: Dec, 2020
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68038-539-7
  • Format: Electronic (PDF)
  • Historical Data: 2020
  • Number of Pages: 140

Report Overview

The global COVID-19 sample collection kits market size is estimated to be valued at USD 12.8 billion in 2020. It is expected to expand at a compound annual growth rate (CAGR) of 3.5% from 2021 to 2027. SARS-CoV-2 sampling is the most critical step in the effective diagnosis of active infection. False and imprecise specimen collection may lead to wrong or misleading test results. As a result, the Centers for Disease Control and Prevention (CDC) and other healthcare organizations have introduced standard procedure and guidance for effective specimen collection and streamline the usage of COVID-19 sample collection solutions, thereby driving the growth. In the current scenario, with lockdown implemented across the globe, key players are working overtime to maintain the production and development scale of swabs and transport media.

Canada COVID-19 sample collection kits market size, by product, 2020 - 2027 (USD Million)

The key stakeholders have collaborated with regional authorities and suppliers for preserving the manufacturing conditions and accelerating the company’s growth in swabs and the viral transport medium market. With the ongoing surge in demand due to the COVID-19 outbreak, companies are concentrating their efforts on strategic products to maximize product output and supply.

The availability of swabs in various configurations for advanced infection detection is one of the key market drivers. For instance, in November 2020, researchers at the University of South Florida (USF) Health have introduced a 3D printed nasal swab prototype for commercial usage. As of 25th November 2020, the organization has developed 100,000+ products, and hospitals across the globe have implemented their 3D files to develop tens of millions more swabs for use in a point-of-care setting.

Furthermore, the advent of antigen tests to fill the timeline and capacity gaps in the testing landscape is anticipated to spur the usage of Nasopharyngeal (NP) swabs across the globe. The U.S. government signed a USD 760 million deal with Abbott over its BinaxNOW COVID-19 Ag Card in August 2020. With this, the government aimed at tripling the national testing capacity. Such collaborations between the diagnostic players and government bodies are anticipated to greatly benefit the swab suppliers in the country.

In August 2020, Puritan Medical Products received USD 51 million contract funding from the U.S. Department of Defense. With this funding, the company plans to expand its manufacturing capacity of flock tip testing swabs. Such supportive government funding programs are expected to significantly bolster the developments in this market.

Product Insights

The swabs segment is estimated to lead the COVID-19 sample collection kits market with a revenue share of 42% in 2020. The key reason is the reliance on a substantial number of approved diagnostic products on the use of NP swabs. According to the CDC, other samples from the respiratory tract can also be collected when the use of NP swabs alone is not sufficient. These include an oropharyngeal swab or a swab from a nostril.

Key players have adopted several measures to accelerate the production and supply of products for COVID-19 sampling. For instance, in November 2020, Puritan received a fund of USD 11.6 million for expansion of its swab manufacturing capabilities to meet the supply of 3 million swabs per month. This additional funding was offered by the Paycheck Protection Program and Health Care Enhancement Act.

On the other hand, with approvals of blood-based serology tests/antibody detection tests for SARS-CoV-2, the demand for blood collection products is increasing. For instance, in November 2020, AnPac Bio-Medical Science Co., Ltd. announced the completion of FDA EUA-antibody test verification for the Roche Elecsys Anti Sars-COV-2 test in its California lab. With this, the company would be able to commence the commercial testing stage.

Application Insights

The use of specimen collection productions for the diagnostics applications segment is expected to account for a maximum revenue share of 69.7% in 2020. This is due to the continuous approvals of diagnostic tests for SARS-CoV-2. As of 1st December 2020, a total of 1,295 tests have been approved by the U.S. FDA under EUAs; out of which 227 are molecular tests, 61 are antibody tests, and 7 are antigen tests for the detection of COVID-19 infection.

Furthermore, continuous development to advance the use of swabs for disease diagnosis is driving the segment. In June 2020, researchers from the Southern University of Denmark (SDU) developed a fully automated robot, i.e. swab robot in collaboration with Lifeline Robotics for swab sampling from the patient. This development is aimed at simplifying the sample extraction process without exposing health care professionals to the risk of infection.

The research segment accounts for low penetration in the global market in terms of revenue generation. However, an increase in the number of R&D programs that deploy sample collection kits to examine the effectiveness of various diagnostic tests is expected to drive the segment. Furthermore, extensive funding to support research on SARS-CoV-2 pathogenesis further boosts the revenue generation in this segment.

Site of Collection Insights

The hospitals and clinics segment is estimated to account for the largest revenue share of 93% in 2020 due to the exponential increase number of hospitalizations related to the coronavirus. As the number of COVID-19 cases is increasing globally, many hospitals are expanding their testing capabilities for the detection of the SARS-CoV-2 virus. This is directly impacting the use of specimen collection products in the hospital settings, thus resulting in the dominance of this segment.

Global COVID-19 sample collection kits market share, by site of collection, 2020 (%)

Several states in the U.S. have reported the challenges of inadequate testing capacity. In Maryland, hospitals’ 86% capacity is already occupied with 1,583 COVID-19 patients statewide as of 1st December 2020. As a result, country officials and local hospitals have begun taking initiatives to ensure sufficient testing capacity to keep pace with a rising number of hospital admissions.

COVID-19 sample collection market for home settings is expected to grow lucratively during the forecast period, as the companies are aiming at patient comfort and safety of healthcare personal. For instance, in November 2020, Mybiopassport, a Swiss biotechnology company, launched its e-Commerce platform for online ordering of the “COVID-19 & Immunity Profile” test, an at-home blood collection test. The test helps determine if the individual has been previously infected by the COVID-19.

Regional Insights

North America is estimated to dominate the market with a 36.1% revenue share in the global 2020 market. The U.S. is one of the most impacted countries worldwide with the highest number of active cases. As of December 7, 2020, the country had performed over 207 million COVID-19 tests which is the highest number of any country as of now. Europe is leading with the second position in terms of revenue. In November 2020, the U.K. government announced the plan of new laboratories to double the testing capacity in the early next year.

The facilities would facilitate the processing of 600,000 more PCR tests per day. On the other hand, the Asia Pacific region is anticipated to grow at the lucrative CAGR over the forecast period. This is because pandemics tend to hit the countries with fragile and underfunded healthcare systems hardest, as there is an inherent disparity between need and purchase power for infection prevention measures such as vaccines.

Government bodies are actively engaged in disease management in the region, which contributes to the revenue growth in the region. For instance, in November 2020, the Indian Council of Medical Research (ICMR) launched a mobile covid-19 RT-PCR laboratory at the ICMR. The government announced its plan to add more such labs to boost testing in the country.

Key Companies & Market Share Insights

The presence of a substantial number of well-established, small, and medium-sized players has led to an increase in market competition. Each player is undertaking multiple business strategies to gain a competitive edge in the market. Some key market participants include Puritan Medical Products; Thermo Fisher Scientific, Inc.; Becton, Dickinson, and Company; COPAN and Diagnostics. With the outbreak of COVID-19, Puritan Medical Products & COPAN Diagnostics have witnessed lucrative growth in their revenue.

These two companies are recognized as the key solution providers in the 2020 global health disaster. Both companies have increased their production capacity to meet the demand for swabs in the U.S. The companies have reported working overtime to effectively address the challenge of swabs shortage. Some other companies that contribute considerably to the market are Quidel Corporation, Trinity Biotech, Formlabs, Trinity Biotech, US Cotton, LabCorp, Quest Diagnostics, Cepheid, and others.

The companies are making constant efforts to ensure that the products are transported and distributed efficiently and quickly as possible. This includes monitoring the global logistics and transportation network as well as taking required actions to overcome the capacity and border constraints in the production and delivery of COVID-19 sample collection products. Some prominent players operating in the COVID-19 sample collection kits market include:

  • Puritan Medical Products

  • COPAN Diagnostics

  • Becton, Dickinson and Company

  • Thermo Fisher Scientific, Inc.

  • Laboratory Corporation of America Holdings

  • Lucence Diagnostics Pte Ltd.

  • Hardy Diagnostics

  • Trinity Biotech

  • Quidel Corporation

  • Quest Diagnostics

  • Danaher Corporation

  • Vitagene Inc.

  • Formlabs

  • HiMedia Laboratories


COVID-19 Sample Collection Kits Market Report Scope

Report Attribute


Market size value in 2020

USD 12.8 billion

Revenue forecast in 2027

USD 16.3 billion

Growth Rate

CAGR of 3.5% from 2021 to 2027

Base year for estimation


Historical data

2020 (as of Nov 2020)

Forecast period

2021 - 2027

Quantitative units

Revenue in USD Million and CAGR from 2021 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, site of collection, region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., France, Italy, Spain, Russia, China, India, South Korea, Australia, Japan, Brazil, Mexico, South Africa, Saudi Arabia

Key companies profiled

Puritan Medical Products; COPAN Diagnostics; Becton, Dickinson and Company; Thermo Fisher Scientific, Inc.; Laboratory Corporation of America Holdings; Lucence Diagnostics Pte Ltd.; Hardy Diagnostics; Trinity Biotech; Quidel Corporation; Quest Diagnostics; Danaher Corporation; Vitagene Inc.; Formlabs; HiMedia Laboratories; VIRCELL S.L.

Customization scope

Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2027. For this study and based on the data available as of November 2020, Grand View Research has segmented the global COVID-19 sample collection kits market report based on product, application, site of collection, and region:

  • Product Outlook (Revenue, USD Million, 2020 - 2027)

    • Swabs

      • Nasopharyngeal (NP) swabs

      • Oropharyngeal (OP) swabs

      • Nasal swabs

    • Viral Transport Media

    • Blood Collection Kits

    • Other Consumables

  • Application Outlook (Revenue, USD Million, 2020 - 2027)

    • Diagnostics

    • Research

  • Site of Collection Outlook (Revenue, USD Million, 2020 - 2027)

    • Hospitals & Clinics

    • Home Test

  • Regional Outlook (Revenue, USD Million, 2020 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • China

      • India

      • South Korea

      • Australia

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • Middle East Africa (MEA)

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.